AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Apollo Endosurgery to Participate in Digestive Disease Week® 2019

May 15, 2019

AUSTIN, Texas--(BUSINESS WIRE)--May 15, 2019--

Apollo Endosurgery, Inc. (“Apollo”) (Nasdaq: APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, announced today its participation during Digestive Disease Week 2019 (“DDW”). DDW will be held May 18-21, 2019 at the San Diego Convention Center in San Diego, California.

Apollo’s OverStitch™ Endoscopic Suturing System and ORBERA® Intragastric Balloon, will be featured in 40 clinical presentations that demonstrate the effectiveness of OverStitch and ORBERA when used across a number of diverse clinical needs.

Apollo will also feature Overstitch Sx, its latest endoscopic suturing device designed for compatibility with single-channel endoscopes with diameters ranging from 8.8mm to 9.8mm. The Overstitch Sx provides a greater number of physicians with access to the benefits of full-thickness flexible endoscopic suturing regardless of their hospital’s selection of endoscopic capital equipment or endoscope manufacturer.

In addition, Apollo will unveil Apollo Care, a nutritional and activity-based patient management platform designed to provide physicians and dietitians the ability to deliver personalized weight loss coaching programs to their patients without the need for frequent in-office visits.

During the conference, DDW will host hands-on workshops for its attendees including sessions that feature the OverStitch and ORBERA technologies. In addition, the Apollo Mobile Learning Center will be in San Diego to support personalized hands-on physician training. The Apollo Mobile Learning Center is a state-of-the-art mobile training facility that allows for advanced endoscopic training programs to be conducted in individual local markets.

About OverStitch™

The OverStitch endoscopic suturing system enables advanced endoscopic surgery by allowing physicians to place full-thickness sutures from a flexible endoscope. This new technology enables a secure approximation of tissue endoscopically and a wide range of less invasive solutions for physicians who treat defects in both the upper and lower GI tract of their patients. Additionally, physicians are leveraging endoscopic suturing to perform a variety of advanced bariatric procedures. For more information regarding OverStitch go to: www.overstitch.com.

About ORBERA®

ORBERA® is an incision-less, non-surgical weight loss solution designed for adult patients suffering from obesity, who are not appropriate for or considering invasive surgery, but for whom diet and exercise or pharmaceutical interventions have not worked.

In a non-surgical (endoscopic) procedure, the thin and deflated ORBERA balloon is placed into the stomach. It is then filled with saline until it’s about the size of a grapefruit. The procedure typically takes about 20 to 30 minutes and the patient can generally go home the same day. At six months, through another non-surgical procedure, the ORBERA balloon is deflated and then removed.

Once the balloon is in place, the patient receives an individually tailored support program through the ORBERA Managed Weight Loss System team of experts to help keep them motivated, coordinate their program and help them work through weight loss barriers to meet their long-term weight loss goals. Coaching takes place over 12 months, even though the balloon is removed after six months. The program is designed to help the patient develop sustainable, healthy habits that will help keep weight off over time.

For more than 20 years, the global medical community has been using intragastric balloons from the makers of ORBERA to help thousands of people lose weight. More than 295,000 ORBERA balloons have been distributed worldwide in over 70 countries.

For additional information regarding ORBERA, please visit www.orbera.com.

For full safety information please visit www.orbera.com/dfu, talk with your doctor, or call Apollo Customer Support at 1-855-MYORBERA.

About Apollo Endosurgery, Inc.

Apollo Endosurgery, Inc. is a medical technology company focused on less invasive therapies to treat various gastrointestinal conditions, ranging from gastrointestinal defect repairs to the interventional treatment of obesity. Apollo’s device-based therapies are an alternative to invasive surgical procedures, thus lowering complication rates and reducing total healthcare costs. Apollo’s products are offered in over 70 countries today and include the OverStitch™ Endoscopic Suturing System, the OverStitch Sx™ Endoscopic Suturing System, and the ORBERA® Intragastric Balloon.

Apollo’s common stock is traded on Nasdaq Global Market under the symbol “APEN.” For more information regarding Apollo, go to: www.apolloendo.com.

© 2018 Apollo Endosurgery, Inc. All rights reserved. Any third-party trademarks used herein are the property of their respective owners.

Cautionary Note on Forward-Looking Statements

Certain statements in this press release are forward-looking statements that are subject to risks and uncertainties that could cause results to be materially different than expectations. Important factors that could cause actual results to differ materially include: the advancement of Apollo products; development of enhancements to Apollo’s existing products and technologies; market acceptance of Apollo’s products; the execution of our gross margin improvement projects; the ability to collect future payments from ReShape; and statements relating to the availability of cash for Apollo’s future operations; Apollo’s ability to support the adoption of its products and its ability to broaden its product portfolio as well as other factors detailed in Apollo’s periodic reports filed with the Securities and Exchange Commission, or SEC, including its Form 10-K for the year ended December 31, 2018 and its Form 10-Q for the three months ended March, 31, 2019. Copies of reports filed with the SEC are posted on Apollo’s website and are available from Apollo without charge. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, Apollo disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190515005844/en/

CONTACT: Media Contact:

Jen Cook, 512-279-5158

jen.cook@apolloendo.comInvestor Contacts:

John Gillings, 512-279-5100

Investor Relations Manager

investor-relations@apolloendo.com

KEYWORD: UNITED STATES NORTH AMERICA TEXAS

INDUSTRY KEYWORD: SURGERY HEALTH BIOTECHNOLOGY MEDICAL DEVICES GENERAL HEALTH

SOURCE: Apollo Endosurgery, Inc.

Copyright Business Wire 2019.

PUB: 05/15/2019 04:00 PM/DISC: 05/15/2019 04:00 PM

http://www.businesswire.com/news/home/20190515005844/en

All contents © copyright 2019 The Associated Press.All rights reserved.